Alzheimer’s Association launches $100m trial combining life-style adjustments and GLP-1s to stop cognitive decline

The Alzheimer’s Association has launched a brand new world medical trial investigating whether or not combining a confirmed multidomain life-style intervention with a GLP-1 agonist can additional cut back the danger of cognitive decline, gentle cognitive impairment (MCI) and dementia in at-risk older adults.

The research, named PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline via Combined Therapy), has $100m in funding and was introduced on the Alzheimer’s Association International Conference (AAIC) 2026 in London. 

It follows the success of an earlier trial, US POINTER, which demonstrated that wholesome life-style interventions — comparable to adjustments in weight-reduction plan, train, coronary heart well being and cognitive problem and social engagement — can defend cognitive operate.

The affiliation referred to as it the “next phase in advancing research focused on risk reduction/prevention strategies for Alzheimer’s and other diseases that cause dementia.”

“PROTECT-Cog builds directly on what we learned from US POINTER and takes the next critical step in prevention science,” mentioned Dr Maria C. Carrillo, Chief Science Officer and Medical Affairs Lead on the Alzheimer’s Association and principal investigator of the research.

By testing a mixed method that targets each life-style and biology, we have now the chance to raised perceive tips on how to meaningfully cut back the danger of cognitive decline earlier than signs start.

GLP-1 receptor agonists have proven promise in decreasing dementia danger, however trials have to this point proven combined outcomes.

Recent analysis, comparable to Novo Nordisk’s Phase III EVOKE trial, discovered that oral semaglutide didn’t gradual cognitive decline in early Alzheimer’s.

In distinction, the agency’s smaller Phase II research, ELAD, demonstrated that liraglutide slowed cognitive decline and mind atrophy by practically 50% in comparison with placebo.

Notably, the literature exhibits that cognitive enhancements are most evident in people with larger BMI or weight problems.

The PROTECT-Cog Study will enrol older adults at elevated danger of cognitive decline and examine two life-style intervention approaches — a structured programme with intensive teaching and assist and a structured-lite programme with the identical core content material however fewer participant touchpoints — to guage their results on cognitive well being.

The research will consider the consequences of a drug that enhances metabolism and immune operate on delaying the development of gentle cognitive impairment, whereas additionally assessing frailty, high quality of life and total well being.

Participants will probably be adopted for three years, with complete cognitive and well being evaluations performed each six months.

“The Alzheimer’s Association is uniquely positioned to lead this next generation of dementia prevention research,” mentioned Dr Heather M. Snyder, Senior Vice President of medical and scientific relations on the Alzheimer’s Association and workers lead on this undertaking.

Through our management of US POINTER, LatAm FINGERS and the World Wide FINGERS Network, the Association has established the worldwide infrastructure, scientific experience and partnerships required to conduct a research of this scale.

• Companies:
• Novo Nordisk Pharmatech

See extra